Hypertension Induced by Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini‐Review
ABSTRACT Hypoxia‐inducible factor prolyl hydroxylase (HIF‐PH) inhibitors are a new class of agents for the treatment of anemia in chronic kidney disease (CKD). Unlike traditional treatments such as erythropoiesis‐stimulating agents (ESAs), HIF‐PH inhibitors are orally administered drugs and may incr...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | The Journal of Clinical Hypertension |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jch.14924 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846116462096285696 |
|---|---|
| author | Wei Zhang Yan Li Ji‐Guang Wang |
| author_facet | Wei Zhang Yan Li Ji‐Guang Wang |
| author_sort | Wei Zhang |
| collection | DOAJ |
| description | ABSTRACT Hypoxia‐inducible factor prolyl hydroxylase (HIF‐PH) inhibitors are a new class of agents for the treatment of anemia in chronic kidney disease (CKD). Unlike traditional treatments such as erythropoiesis‐stimulating agents (ESAs), HIF‐PH inhibitors are orally administered drugs and may increase endogenous erythropoietin and improve iron homeostasis. However, a significant concern is their possible side effect on blood pressure. The current mini‐review summarizes the data of 26 randomized controlled (placebo or ESAs) trials on six different HIF‐PH inhibitors with regard to their potential influence on blood pressure and hypertension in the management of anemia in CKD. Overall, the use of HIF‐PH inhibitors was associated with a higher risk of hypertension than placebo (pooled risk ratio 1.36, 95% confidence interval [CI] 1.16–1.59), but a lower risk of hypertension than ESA treatment (pooled risk ratio 0.92, 95% CI 0.86–0.98), especially in CKD patients not undergoing dialysis (pooled risk ratio 0.85, 95% CI 0.73–0.98). This review highlights the importance of blood pressure monitoring during the treatment of HIF‐PH inhibitors, especially out‐of‐office blood pressure measurement. |
| format | Article |
| id | doaj-art-5f8519f8c9ab46f6af2df935715b317d |
| institution | Kabale University |
| issn | 1524-6175 1751-7176 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Journal of Clinical Hypertension |
| spelling | doaj-art-5f8519f8c9ab46f6af2df935715b317d2024-12-18T19:30:42ZengWileyThe Journal of Clinical Hypertension1524-61751751-71762024-12-0126121375138310.1111/jch.14924Hypertension Induced by Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini‐ReviewWei Zhang0Yan Li1Ji‐Guang Wang2Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai ChinaABSTRACT Hypoxia‐inducible factor prolyl hydroxylase (HIF‐PH) inhibitors are a new class of agents for the treatment of anemia in chronic kidney disease (CKD). Unlike traditional treatments such as erythropoiesis‐stimulating agents (ESAs), HIF‐PH inhibitors are orally administered drugs and may increase endogenous erythropoietin and improve iron homeostasis. However, a significant concern is their possible side effect on blood pressure. The current mini‐review summarizes the data of 26 randomized controlled (placebo or ESAs) trials on six different HIF‐PH inhibitors with regard to their potential influence on blood pressure and hypertension in the management of anemia in CKD. Overall, the use of HIF‐PH inhibitors was associated with a higher risk of hypertension than placebo (pooled risk ratio 1.36, 95% confidence interval [CI] 1.16–1.59), but a lower risk of hypertension than ESA treatment (pooled risk ratio 0.92, 95% CI 0.86–0.98), especially in CKD patients not undergoing dialysis (pooled risk ratio 0.85, 95% CI 0.73–0.98). This review highlights the importance of blood pressure monitoring during the treatment of HIF‐PH inhibitors, especially out‐of‐office blood pressure measurement.https://doi.org/10.1111/jch.14924chronic kidney diseaseerythropoietinhypertensionhypoxia‐inducible factorprolyl hydroxylase inhibitorsrenal anemia |
| spellingShingle | Wei Zhang Yan Li Ji‐Guang Wang Hypertension Induced by Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini‐Review The Journal of Clinical Hypertension chronic kidney disease erythropoietin hypertension hypoxia‐inducible factor prolyl hydroxylase inhibitors renal anemia |
| title | Hypertension Induced by Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini‐Review |
| title_full | Hypertension Induced by Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini‐Review |
| title_fullStr | Hypertension Induced by Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini‐Review |
| title_full_unstemmed | Hypertension Induced by Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini‐Review |
| title_short | Hypertension Induced by Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini‐Review |
| title_sort | hypertension induced by hypoxia inducible factor prolyl hydroxylase inhibitors in treating anemia in patients with chronic kidney disease a mini review |
| topic | chronic kidney disease erythropoietin hypertension hypoxia‐inducible factor prolyl hydroxylase inhibitors renal anemia |
| url | https://doi.org/10.1111/jch.14924 |
| work_keys_str_mv | AT weizhang hypertensioninducedbyhypoxiainduciblefactorprolylhydroxylaseinhibitorsintreatinganemiainpatientswithchronickidneydiseaseaminireview AT yanli hypertensioninducedbyhypoxiainduciblefactorprolylhydroxylaseinhibitorsintreatinganemiainpatientswithchronickidneydiseaseaminireview AT jiguangwang hypertensioninducedbyhypoxiainduciblefactorprolylhydroxylaseinhibitorsintreatinganemiainpatientswithchronickidneydiseaseaminireview |